0.1500
0.0000
(0.00%)
At close: January 27 at 3:00:00 PM EST
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
73.0000
814.0000
9,404.0000
10,126.0000
Cost of Revenue
125.0000
616.0000
4,316.0000
4,424.0000
Gross Profit
-52.0000
198.0000
5,088.0000
5,702.0000
Operating Expense
21,752.0000
26,075.0000
37,466.0000
47,808.0000
Operating Income
-21,804.0000
-25,877.0000
-32,378.0000
-42,106.0000
Net Non Operating Interest Income Expense
35.0000
-11.0000
-127.0000
-182.0000
Other Income Expense
13,464.0000
18,055.0000
2,318.0000
-566.0000
Pretax Income
-8,305.0000
-7,833.0000
-30,187.0000
-42,854.0000
Net Income Common Stockholders
-8,305.0000
-7,833.0000
-30,187.0000
-42,854.0000
Average Dilution Earnings
--
-4,949.0000
--
-2,914.0000
Diluted NI Available to Com Stockholders
-13,254.0000
-12,782.0000
-30,187.0000
-45,768.0000
Basic EPS
-0.60
-1.14
-9.50
-27.75
Diluted EPS
-0.60
-1.67
-9.50
-29.00
Basic Average Shares
7,842.2240
6,853.1690
3,200.5600
1,551.1720
Diluted Average Shares
8,601.3860
7,665.1900
3,200.5600
1,574.6950
Total Operating Income as Reported
-18,302.0000
-22,373.0000
-33,686.0000
-45,940.0000
Total Expenses
21,877.0000
26,691.0000
41,782.0000
52,232.0000
Net Income from Continuing & Discontinued Operation
-8,305.0000
-7,833.0000
-30,187.0000
-42,854.0000
Normalized Income
-21,698.0000
-25,805.0000
-32,289.0000
-41,934.0000
Interest Expense
--
11.0000
127.0000
--
Net Interest Income
35.0000
-11.0000
-127.0000
-182.0000
EBIT
-8,812.0000
-7,822.0000
-30,060.0000
-42,106.0000
EBITDA
-7,612.0000
-6,315.0000
-27,218.0000
-38,843.0000
Reconciled Cost of Revenue
125.0000
616.0000
4,316.0000
4,424.0000
Reconciled Depreciation
1,200.0000
1,507.0000
2,842.0000
3,263.0000
Net Income from Continuing Operation Net Minority Interest
-8,305.0000
-7,833.0000
-30,187.0000
-42,854.0000
Total Unusual Items Excluding Goodwill
13,393.0000
17,972.0000
2,102.0000
-920.0000
Total Unusual Items
13,393.0000
17,972.0000
2,102.0000
-920.0000
Normalized EBITDA
-21,005.0000
-24,287.0000
-29,320.0000
-37,923.0000
12/31/2020 - 8/17/1999
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
GSTC GlobeStar Therapeutics Corporation
0.0003
0.00%
RSPI RespireRx Pharmaceuticals Inc.
0.0011
+37.50%
TXTM ProText Mobility, Inc.
0.0009
+12.50%
RLYB Rallybio Corporation
0.8889
+1.02%
AXIM AXIM Biotechnologies, Inc.
0.0031
+14.81%
IBO Impact BioMedical Inc.
1.7000
-5.03%
XBIT XBiotech Inc.
3.4800
-4.40%
NXTC NextCure, Inc.
0.7992
-1.64%
GRCE Grace Therapeutics, Inc.
3.4500
-7.75%
MBRX Moleculin Biotech, Inc.
1.6600
-1.19%